4.3 Review

Major pathways of the reno-cardiovascular link: the sympathetic and renin-angiotensin systems

期刊

KIDNEY INTERNATIONAL SUPPLEMENTS
卷 1, 期 1, 页码 13-16

出版社

ELSEVIER SCIENCE INC
DOI: 10.1038/kisup.2011.3

关键词

chronic kidney disease; hypertension; renin angiotensin; sympathetic activity

资金

  1. Abbott Laboratories
  2. F. Hoffmann-La Roche
  3. Amgen
  4. Fresenius Medical Care Holdings
  5. Roche Spain
  6. Abbott Spain
  7. Spanish Government
  8. Janssen-Cileg
  9. Astellas Pharma
  10. EU
  11. Shire
  12. Genzyme
  13. Novartis AG
  14. Sandoz
  15. Pfizer
  16. Baxter
  17. Medtronic
  18. Ardian
  19. Merck
  20. Affymax
  21. Takeda Pharmaceutical Company
  22. Daiichi Sankyo
  23. Celgene
  24. Watson Pharmaceuticals
  25. Rockwell Medical
  26. Medscape
  27. FMC
  28. Merck Sharp Dohme

向作者/读者索取更多资源

Chronic kidney disease is often characterized by enhanced activity of the renin-angiotensin system (RAS) and the sympathetic nervous system. Independent of their effect on blood pressure, these systems also contribute to the pathogenesis of both structural and functional cardiovascular abnormalities and contribute importantly to clinical outcome. There is much evidence that the diseased kidneys are of central importance in the pathogenesis of both abnormalities. Inhibitors of the RAS also reduce sympathetic overactivity. Future research should be aimed at addressing the pathophysiological mechanisms causing the enhanced activities. Given the fact that even a small kidney lesion can cause enhanced activity of the RAS and the sympathetic nervous system, it is likely that these pathophysiological mechanisms are operational in more disease conditions, including essential hypertension, heart failure, and obesity/metabolic syndrome.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据